How leftover fish skins landed this founder a billion-dollar exit: ‘My philosophy has always been to have fun’

· Source: Sifted · Field: Business & Management — Entrepreneurship & Start-ups, Corporate Strategy & Leadership · Depth: Fundamental Awareness, short

Summary

Kerecis, an Icelandic biotech company founded by Fertram Sigurjonsson, was sold for an estimated $1.2 billion in 2023. The company specializes in using fish skin, specifically from Atlantic cod, to develop regenerative tissue products for wound healing and reconstructive surgery. Sigurjonsson's approach involved transforming a discarded byproduct of the fishing industry into a high-value medical material. Kerecis, Iceland's only unicorn, has expanded significantly, establishing a presence in the US and other markets, and employs over 720 people. The company's success is attributed to its innovative use of a sustainable resource and its focus on a clear, unmet medical need, demonstrating Iceland's capacity for innovation despite its small population.

Key takeaway

For investors evaluating biotech opportunities, consider companies that repurpose industrial byproducts into high-value medical applications. Your due diligence should prioritize ventures with clear, unmet market needs and a sustainable resource base, as demonstrated by Kerecis's $1.2 billion exit. Look for innovative approaches that transform waste into essential products, indicating strong potential for both impact and financial return.

Key insights

Transforming industrial byproducts into high-value medical solutions can yield significant economic success.

Principles

Method

Kerecis developed regenerative tissue products from Atlantic cod fish skin, a byproduct of the fishing industry, to address wound healing and reconstructive surgery needs.

In practice

Topics

Best for: Investor, Entrepreneur, Executive, Consultant

Related on AIssential

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Sifted.